56 unknown, 26 recruiting, 11 completed, 9 not yet recruiting. 23 Not applicable, 20 Phase 2, 14 Phase 3, 7 Phase 1, 5 Phase 4.
Follow Fifth Affiliated Hospital, Sun Yat-Sen University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases Dalpiciclib, Endocrine Therapy of Physician's Choice, Brain Radiotherapy - Breast Cancer, Brain Metastases | Phase 2 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 46 | 2026-06-01 | 2026-04-30 |
| Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM Henagliflozin Proline Tablets treatment, Metformin XR treatment - Diabetes Type 2 | Phase 4 | Not yet recruiting | Bin Lu | 116 | 2025-12-30 | 2026-01-07 |
| Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid Houyanqing Oral Liquid, Conventional Treatment for Radiation-Induced Oral Mucositis - Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis | Phase 3 | Recruiting | Sun Yat-sen University | 386 | 2025-12-16 | 2026-05-07 |
| Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors Lucanisatuzumab plus tagolimumab - Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 35 | 2025-11-13 | 2026-05-08 |
| Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC toripalimab, capecitabine - Esophageal Cancer, Chemoradiotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 242 | 2025-09-10 | 2026-04-21 |
| Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion Computer-Aided Diagnosis System for Preoperative Prediction of MVI in HCC - Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI) | Recruiting | Chinese Academy of Sciences | 400 | 2025-09-01 | 2025-09-12 | |
| Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer Reduced-Target Radiotherapy, Conventional Full-Target Radiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Ming-Yuan Chen | 166 | 2025-08-20 | 2025-12-09 |
| Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT Trial Steerable FANS, Conventional FANS - Kidney Stones | Not applicable | Recruiting | The First Affiliated Hospital of Guangzhou Medical University | 400 | 2025-03-16 | 2025-03-27 |
| Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI Nasopharyngeal Cancinoma (NPC), Distant Metastasis | Recruiting | Sun Yat-sen University | 500 | 2025-02-15 | 2025-02-25 | |
| Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma Zuberitamab, Bendamustine - Follicular Lymphoma (FL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 50 | 2025-02-01 | 2025-01-03 |
| Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: cfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection Nasopharyngeal Carcinoma (NPC) | Active not recruiting | First Affiliated Hospital, Sun Yat-Sen University | 700 | 2024-12-25 | 2026-09-02 | |
| The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia Babaodan Capsule - Radiation Pneumonitis | Phase 2 | Unknown | Fifth Affiliated Hospital, Sun Yat-Sen University | 30 | 2024-12-05 | 2024-03-20 |
| A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules Solitary Lung Nodule, Multiple Pulmonary Nodules | Not yet recruiting | Guangdong Provincial People's Hospital | 1184 | 2024-12-01 | 2024-12-02 | |
| "Xijiang Project" Screening Cohort for NPC EBV antibodies test, EBV DNA test, epidemiological information survey - Nasopharyngeal Carcinoma (NPC), Screening | Recruiting | Ming-Yuan Chen | 1000000 | 2024-11-14 | 2026-09-01 | |
| Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） Orelabrutinib Oral Tablet, R-CHOP Protocol - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Sun Yat-sen University | 39 | 2024-11-01 | 2024-10-22 |
| Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) Zanubrutinib, Rituximab - Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | Phase 2 | Active not recruiting | Sun Yat-sen University | 42 | 2024-10-30 | 2026-09-15 |
| Efficacy and Safety of Transbronchial Bronchoscopic Thermal Vapor Ablation (BTVA) in Heterogeneous Emphysema Transbronchial Endoscopic Thermal Vapor Ablation - Heterogeneous Emphysema | Not yet recruiting | Ye Gu | 51 | 2024-10-13 | 2024-10-15 | |
| Building a Traditional Chinese Medicine Clinical Diagnosis and Treatment Database Observational study, non intervention - Medicine, Chinese Traditional, Artificial Intelligence | Unknown | Fifth Affiliated Hospital, Sun Yat-Sen University | 80000 | 2024-08-01 | 2024-07-29 | |
| Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) Stereotactic body radiotherapy, Sintilimab - Hepatocellular Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 140 | 2024-04-05 | 2024-11-18 |
| Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma. Endoscopic nasopharyngectomy followed close follow-up, Intensity-modulated Radiotherapy - Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy | Not applicable | Recruiting | Sun Yat-sen University | 442 | 2024-03-25 | 2024-08-01 |
Showing 20 of 110. Sign in to see all of them.
Nasopharyngeal Carcinoma (17) · Carcinoma, Hepatocellular (7) · Carcinoma, Non-Small-Cell Lung (5) · Esophageal Squamous Cell Carcinoma (5) · Esophageal Neoplasms (4) · Liver Cirrhosis (4) · Breast Neoplasms (3) · COVID-19 (3) · Hypertensive Nephropathy (3) · Lymphatic Metastasis (3) · Renal Insufficiency, Chronic (3) · Squamous Cell Carcinoma of Head and Neck (3) · Brain Neoplasms (2) · Diabetes Mellitus, Type 2 (2) · Hypertension, Portal (2)
Cisplatin (9) · Capecitabine (5) · Radiotherapy, Intensity-Modulated (5) · Gemcitabine (4) · toripalimab (4) · Losartan (3) · Radiotherapy (3) · sintilimab (3) · Bevacizumab (2) · Carboplatin (2) · Fluorouracil (2) · Indocyanine Green (2) · Induction Chemotherapy (2) · Injections (2) · Pemetrexed (2)
China (95) · Germany (1) · Italy (1) · South Korea (1) · United States (1)
Cheng Wang, Director (3) · Mian Xi, MD (3) · Ming-Yuan Chen, MD,PhD (3) · Xi Liu, PhD (3) · Hong Shan, MD (2) · Hong Shan, Ph.D (2) · Jun Ma, M.D. (2) · Qi Zeng, Doctor (2) · Shaolin Li (2) · Shaoxuan Liu (2) · Zhigang Liu, M.D. (2) · Ashish Shrestha (1) · Bon-Kwon Koo, MD, PhD (1) · Changxi Wang, M.D., Ph.D. (1) · Di Dong, PhD (1)
PMID 36990609, PMID 10512902, PMID 11783768, PMID 12411653, PMID 12437537, PMID 12587706, PMID 12826970, PMID 14631835, PMID 14703199, PMID 14707332, PMID 15025597, PMID 15570202, PMID 15665258, PMID 18313273, PMID 18396107, PMID 20003546, PMID 20217277, PMID 20446945, PMID 20595216, PMID 21174172, PMID 21874323, PMID 21926976, PMID 22154591, PMID 22245781, PMID 23282124, PMID 23374478, PMID 23642437, PMID 23647568, PMID 23658246, PMID 23713578, PMID 24045403, PMID 24126585, PMID 24360117, PMID 24530176, PMID 24825112, PMID 24968929, PMID 25250628, PMID 25487303, PMID 25497558, PMID 25575253, PMID 25674530, PMID 25904751, PMID 25911312, PMID 25947573, PMID 26041362, PMID 26089178, PMID 26354650, PMID 26703419, PMID 26808342, PMID 26912007